Zacks Research Analysts Lift Earnings Estimates for A

Agilent Technologies, Inc. (NYSE:A) – Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for Agilent Technologies in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $1.39 for the quarter, up from their previous estimate of $1.35. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.47 EPS.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company lowered their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Robert W. Baird lowered their price target on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Sanford C. Bernstein cut their price objective on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. lowered their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $146.15.

Agilent Technologies Stock Performance

A opened at $121.96 on Monday. The stock has a 50-day moving average of $136.34 and a 200-day moving average of $137.16. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies has a 52-week low of $117.17 and a 52-week high of $155.35. The company has a market cap of $34.77 billion, a PE ratio of 28.04, a price-to-earnings-growth ratio of 3.39 and a beta of 1.11.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds have recently made changes to their positions in the company. Sienna Gestion increased its holdings in Agilent Technologies by 29.8% during the 4th quarter. Sienna Gestion now owns 78,445 shares of the medical research company’s stock valued at $10,537,000 after purchasing an additional 17,991 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Agilent Technologies in the third quarter valued at about $14,848,000. Sequoia Financial Advisors LLC lifted its position in Agilent Technologies by 8.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company’s stock worth $4,554,000 after buying an additional 2,664 shares in the last quarter. S.E.E.D. Planning Group LLC grew its holdings in Agilent Technologies by 12.7% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock worth $5,721,000 after acquiring an additional 4,805 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in Agilent Technologies by 16.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 49,288 shares of the medical research company’s stock valued at $6,621,000 after acquiring an additional 6,802 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the transaction, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.26% of the company’s stock.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.81%. Agilent Technologies’s dividend payout ratio is currently 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.